Morgan Stanley set a CHF 88 price objective on Novartis AG (VTX:NOVN) in a research note published on Wednesday morning. The brokerage currently has a buy rating on the stock.

Other equities research analysts have also issued research reports about the stock. Jefferies Group LLC set a CHF 100 price target on shares of Novartis AG and gave the company a buy rating in a report on Monday, June 5th. HSBC Holdings plc set a CHF 85 price target on shares of Novartis AG and gave the company a buy rating in a report on Wednesday, June 21st. Kepler Capital Markets set a CHF 88 price target on shares of Novartis AG and gave the company a buy rating in a report on Tuesday, July 4th. Sanford C. Bernstein set a CHF 94 price target on shares of Novartis AG and gave the company a buy rating in a report on Tuesday, July 18th. Finally, Societe Generale set a CHF 91 price target on shares of Novartis AG and gave the company a buy rating in a report on Wednesday, July 19th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of CHF 84.21.

Novartis AG (VTX:NOVN) opened at 81.65 on Wednesday. Novartis AG has a 52 week low of CHK 67.40 and a 52 week high of CHK 84.35. The stock’s 50 day moving average is CHK 80.28 and its 200-day moving average is CHK 76.78.

WARNING: “Morgan Stanley Reiterates “CHF 88” Price Target for Novartis AG (NOVN)” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/morgan-stanley-reiterates-chf-88-price-target-for-novartis-ag-novn/1461920.html.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.